Biophysical and physiological properties of a modified porcine surfactant enriched with surfactant protein A.
Surfactant protein A (SP-A), a major protein component of natural pulmonary surfactant, is absent in exogenous surfactants currently used in clinical practice. We investigated the physical and physiological properties of one of these modified natural surfactants (Curosurf) after enrichment with 5% SP-A (SP-A-Curosurf). A pulsating bubble system was used for in vitro assessments and ventilated newborn rabbits for evaluation of in vivo effects. In the presence of various potential inhibitors (meconium 5 mg.mL-1, fibrinogen 5 mg.mL-1, albumin 25 mg.mL-1, or whole serum proteins 25 mg.mL-1), Curosurf at a concentration of 5 mg.mL-1 was inactivated while SP-A-Curosurf and natural porcine surfactant at the same concentration had normal maximum and minimum surface tension. This protective effect of SP-A was calcium dependent. In immature newborn rabbits, the improvement of lung-thorax compliance observed after treatment with 100 mg.kg-1 of SP-A-Curosurf was equivalent to that obtained with 200 mg.kg-1 of Curosurf. Similarly, in near-term newborn rabbits with respiratory failure induced by instillation of fibrinogen via the airways, the increase in compliance after administration of 100 mg.kg-1 of SP-A-Curosurf corresponded to that seen after treatment with 200 mg.kg-1 of Curosurf, whereas Curosurf at a dose of 100 mg.kg-1 had no substantial effect. Our data thus indicate that surfactant protein A increases the resistance of Curosurf to inactivation under in vivo conditions.
Sun
B
B
Division for Experimental Perinatal Pathology, Karolinska Hospital, Stockholm, Sweden.
Curstedt
T
T
Lindgren
G
G
Franzén
B
B
Alaiya
A A
AA
Calkovská
A
A
Robertson
B
B
D000418:Albumins / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001688:Biological Products; D004492:Edetic Acid / Q000494:pharmacology; D005340:Fibrinogen / Q000494:pharmacology; D006339:Heart Rate; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007231:Infant, Newborn; D008170:Lung Compliance; D008470:Meconium; D008970:Molecular Weight; D010743:Phospholipids; D011510:Proteolipids / Q000737:chemistry / Q000494:pharmacology*; D037662:Pulmonary Surfactant-Associated Protein A; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants / Q000737:chemistry / Q000494:pharmacology*; D011817:Rabbits; D012127:Respiratory Distress Syndrome, Newborn / Q000503:physiopathology*; D013499:Surface Properties; D013552:Swine
D000418:Albumins; D001688:Biological Products; D010743:Phospholipids; D011510:Proteolipids; D037662:Pulmonary Surfactant-Associated Protein A; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants; D005340:Fibrinogen; D004492:Edetic Acid; C068291:poractant alfa